Curis Lifesciences Limited

Curis Lifesciences Limited (CURIS) is a micro-cap Healthcare company valued at ₹161 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move

Curis Lifesciences Limited last traded at ₹199, unchanged on the day.

Recent developments

On 2026-03-31, the company reported its latest financial results, showing revenue of ₹33 crore and net profit of ₹3 crore. The company has not paid dividends despite reporting profits, which may indicate a focus on reinvestment rather than shareholder returns.

Financial performance

The company's business is improving, with annual revenue rising 23.4% and net profit growing 13.3% year-on-year. However, the latest quarter saw revenue fall 4.8% compared to the same quarter a year earlier, and net profit dropped 32.2%.

Valuation multiples

The stock trades at 23.3 times earnings, a discount to the Healthcare median of 32.0, 3.56 times book value.

Things to watch

The company's net profit margin narrowed by 1.0 percentage points to 11.4%, and the latest quarter's net profit fell 32.2% compared to the same quarter a year earlier. The stock is 12.0% below its 52-week high, and the company has not paid dividends despite repeated profits.

Where it stands

Curis Lifesciences Ltd ended the latest quarter with revenue of ₹33 crore and net profit of ₹3 crore, showing a significant drop in profitability compared to the same quarter a year earlier. The company's net profit margin has also declined, and it has not distributed any dividends to shareholders despite reporting profits.

Summarised by DocStoX's model on 2026-10-04 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.